Back to Authors

Dye, Andrew

A5069501943 | I4210139800

Mayo Clinic

Arbutus Biopharma (Canada)

Citations 1

A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2547-2547

10.1200/jco.2016.34.15_suppl.2547